Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

ClinicalTrials.gov ID: NCT07301255

Public ClinicalTrials.gov record NCT07301255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.

Study identification

NCT ID
NCT07301255
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Enveda Therapeutics
Industry
Enrollment
50 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 8, 2026
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026
Last update posted
Jul 28, 2026

2026 – 2027

United States locations

U.S. sites
18
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Enveda Investigative Site Birmingham Alabama 35209 Recruiting
Enveda Investigative Site Los Angeles California 90025 Recruiting
Enveda Investigative Site San Jose California 95117 Recruiting
Enveda Investigative Site West Hills California 91307 Recruiting
Enveda Investigative Site Colorado Springs Colorado 80907 Recruiting
Enveda Investigative Site Hialeah Florida 33012 Recruiting
Enveda Investigative Site Miami Florida 33135 Recruiting
Enveda Investigative Site Albany Georgia 31707 Recruiting
Enveda Investigative Site Maryville Illinois 62062 Recruiting
Enveda Investigative Site Kansas City Kansas 66160 Recruiting
Enveda Investigative Site Owensboro Kentucky 42301 Recruiting
Enveda Investigative Site Southfield Michigan 48075 Recruiting
Enveda Investigative Site St Louis Missouri 63141 Recruiting
Enveda Investigative Site Clackamas Oregon 97015 Recruiting
Enveda Investigative Site Medford Oregon 97504 Recruiting
Enveda Investigative Site North Charleston South Carolina 29406 Recruiting
Enveda Investigative Site McKinney Texas 75069 Recruiting
Enveda Investigative Site Madison Wisconsin 53792 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07301255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 28, 2026 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07301255 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →